During the past decade, Stauferklinikum Schwäbisch Gmünd conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 9 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 5 clinical trials were completed. i.e. 41.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Stauferklinikum Schwäbisch Gmünd" #1 sponsor was "University of Ulm" with 9 trials, followed by "German CLL Study Group" with 7 trials sponsored, "Celgene" with 3 trials sponsored, "Kartos Therapeutics, Inc." with 3 trials sponsored and "Pfizer" with 3 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Stauferklinikum Schwäbisch Gmünd" #1 collaborator was "AbbVie" with 2 trials as a collaborator, "Cancer Trials Ireland" with 2 trials as a collaborator, "German CLL Study Group" with 2 trials as a collaborator, "Nordic CLL Study Group (NCLLSG)" with 2 trials as a collaborator and "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator. Other collaborators include 19 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "Stauferklinikum Schwäbisch Gmünd" are "Chronic Lymphocytic Leukemia" (6 trials), "Acute Myeloid Leukemia (AML)" (5 trials), "Primary Myelofibrosis" (3 trials), "Acute Myeloid Leukemia" (2 trials) and "Anemia" (2 trials). Many other conditions were trialed in "Stauferklinikum Schwäbisch Gmünd" in a lesser frequency.

Most popular intervention types in "Stauferklinikum Schwäbisch Gmünd" are "Drug" (39 trials), "Biological" (8 trials), "Other" (5 trials), "Device" (2 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Obinutuzumab" (7 trials), "Rituximab" (6 trials), "Cytarabine" (5 trials), "Venetoclax" (5 trials) and "Cyclophosphamide" (4 trials). Other intervention names were less common.

The vast majority of trials in "Stauferklinikum Schwäbisch Gmünd" are 44 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Stauferklinikum Schwäbisch Gmünd". undefined are not yet recruiting, 9 are recruiting, 15 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Stauferklinikum Schwäbisch Gmünd, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Stauferklinikum Schwäbisch Gmünd, 2 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".

Stauferklinikum Schwäbisch Gmünd has several departments that took part in Clinical trials: "Kliniken Ostalb Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin" - 7 trials